跳至主要内容
临床试验/NCT02528747
NCT02528747已完成不适用

A Multi-Center Observational Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate (BONDORAL)

Hoffmann-La Roche0 个研究点目标入组 582 人开始时间: 2009年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
582
主要终点
Change in bone pain according to Visual Analog Scale (VAS) score

研究概览

简要总结

This observational, multicenter survey is designed to assess the efficacy of oral ibandronate in adults with breast cancer and metastatic bone disease. Data on the use of ibandronate in clinical practice will be collected from Hungarian patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults at least 18 years of age
  • Histologically confirmed breast cancer with bone metastasis
  • Receiving or indicated for the tablet formulation of ibandronate according to the summary of product characteristics (SmPC) and local labeling

排除标准

  • Contraindication to ibandronate according to SmPC
  • Ongoing participation in any trial evaluating the efficacy and/or safety of ibandronate

结局指标

主要结局

Change in bone pain according to Visual Analog Scale (VAS) score

时间窗: From Baseline to the end of 1 year

次要结局

  • Compliance with tablet formulation of ibandronate according to Case Report Form (CRF) questionnaire(Up to approximately 1 year)
  • Incidence of adverse events(Up to approximately 1 year)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验